A major drawback of<unk>  therapy is its association with severe and potentially fatal immunological adverse effects due to T cell activation and proliferation, occurring in ten to twenty percent of patients. Serious adverse effects include stomach pain, bloating, constipation, diarrhea, fever, trouble breathing, and urinating problems. A "risk evaluation and mitigation strategy" informs prescribers of the potential risks. Between 5.7 and 9.1% of individuals treated with<unk>  develop checkpoint inhibitor induced colitis. Individual cases of severe neurologic disorders following<unk>  have been observed, including acute inflammatory demyelination polyneuropathy and an ascending motor paralysis, and myasthenia gravis.
Ipilimumab
Pembrolizumab
Daratumumab
Axitinib
Teprotumumab
Siltuximab
Blinatumomab
Ofatumumab